Asia On The Move: Xian Janssen China President Thad Huston Leaves
This article was originally published in PharmAsia News
The change of seasons coincides with a flurry of key personnel moves in the Asian pharmaceutical scene. Xian Janssen China President Thad Huston moves up, Simcere vice president Jie Liu D’Elia joins BMS. Personnel changes also took place in Takeda, Lupin, inVentive Health and the Japan Pharmaceutical Manufacturers Association.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.